United Therapeuticsvs.Vertex Pharmaceuticals
UTHR vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 6.1× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.0 vs 30.7); year to date, Vertex Pharmaceuticals leads (+20.8% vs +5.3%).
Side by side
| UTHR | VRTX | |
|---|---|---|
| Market cap | $22.3B | $135B |
| Price | $518.53 | $552.85 |
| Today | +1.1% | +1.0% |
| Return YTD | +5.3% | +20.8% |
| Return 1Y | +64.3% | +38.6% |
| P/E | 17.0 | 30.7 |
| P/S | 7.1 | 10.7 |
| P/B | 3.5 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More UTHR & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.